New hope for Tough-to-Treat blood cancer: trial tests adding a pill to standard therapy
Disease control
Not yet recruiting
This study is testing if adding a new oral drug, golidocitinib, to a standard chemotherapy and immunotherapy combination works better for people with newly diagnosed, advanced NK/T-cell lymphoma. It will compare the new three-drug combination against the standard two-drug combina…
Phase: PHASE2 • Sponsor: WEI XU • Aim: Disease control
Last updated Mar 30, 2026 14:33 UTC